News & Updates

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021 by

Bayer reveals major transformation in its pharmaceutical business with the use of breakthrough innovations aimed at helping patients with difficult-to-treat conditions.

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021

Heart failure post-MI more frequent in women than men

04 Feb 2021 by

Women who are hospitalized for myocardial infarction (MI) have a higher risk of long-term negative cardiovascular outcomes compared with men, according to a recent study from Canada.

Heart failure post-MI more frequent in women than men

04 Feb 2021

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

04 Feb 2021 by

Using the urate-lowering drug febuxostat does not come with an excess risk of major cardiovascular (CV) events compared with allopurinol for gout treatment, according to the EMA*-mandated post-authorization safety study, FAST**.

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

04 Feb 2021

Low-dose aspirin improves reproductive outcomes in women with pregnancy loss

04 Feb 2021

Preconception use of low-dose aspirin (LDA) at least 4 days per week is associated with better reproductive outcomes for women who have had one or two pregnancy losses, suggests a study. Increasing adherence to daily LDA may help improve effectiveness.

Low-dose aspirin improves reproductive outcomes in women with pregnancy loss

04 Feb 2021

Early anticoagulation does not improve survival in critically ill COVID-19 patients

04 Feb 2021 by

Early therapeutic anticoagulation among critically ill adults with the coronavirus disease 2019 (COVID-19) appears to have no significant impact on survival in the target trial emulation, suggests a study.

Early anticoagulation does not improve survival in critically ill COVID-19 patients

04 Feb 2021

Beta blockers plus diuretic tied to lowest SBP in OSA patients

04 Feb 2021

Obstructive sleep apnoea (OSA) patients on antihypertension medication often have poorly controlled blood pressure (BP), reveals a study. Treatment with beta blockers alone or in combination with a diuretic appears to result in the lowest systolic (S)BP in this clinical cohort.

Beta blockers plus diuretic tied to lowest SBP in OSA patients

04 Feb 2021

PPI may weaken response to infliximab in inflammatory bowel disease

04 Feb 2021

Inflammatory bowel disease patients using a proton pump inhibitor (PPI) appear to have lower odds of achieving remission on infliximab therapy, a study reports.

PPI may weaken response to infliximab in inflammatory bowel disease

04 Feb 2021

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

03 Feb 2021 by

Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

03 Feb 2021

COVID-19 vs flu: Far more fatal and damaging

03 Feb 2021 by

While it is tempting to draw lessons from previous influenza pandemic in dealing with the relatively new COVID-19 pandemic, emerging data show just how much deadlier COVID-19 intrinsically is compared with influenza — with higher rates of deaths and complications among hospitalized patients with COVID-19.

COVID-19 vs flu: Far more fatal and damaging

03 Feb 2021

RASP inhibition gets high marks in early trial of dry eye disease

03 Feb 2021 by

The novel reactive aldehyde species (RASP) inhibitor reproxalap delivers rapid and meaningful control of signs and symptoms of dry eye disease, according to the results of a phase IIb trial.

RASP inhibition gets high marks in early trial of dry eye disease

03 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

Heart failure post-MI more frequent in women than men

Heart failure post-MI more frequent in women than men

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

Low-dose aspirin improves reproductive outcomes in women with pregnancy loss

Low-dose aspirin improves reproductive outcomes in women with pregnancy loss

Early anticoagulation does not improve survival in critically ill COVID-19 patients

Early anticoagulation does not improve survival in critically ill COVID-19 patients

Beta blockers plus diuretic tied to lowest SBP in OSA patients

Beta blockers plus diuretic tied to lowest SBP in OSA patients

PPI may weaken response to infliximab in inflammatory bowel disease

PPI may weaken response to infliximab in inflammatory bowel disease

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

COVID-19 vs flu: Far more fatal and damaging

COVID-19 vs flu: Far more fatal and damaging

RASP inhibition gets high marks in early trial of dry eye disease

RASP inhibition gets high marks in early trial of dry eye disease